SE460947B - En multiple-unit-dos komposition av l-dopa - Google Patents

En multiple-unit-dos komposition av l-dopa

Info

Publication number
SE460947B
SE460947B SE8603582A SE8603582A SE460947B SE 460947 B SE460947 B SE 460947B SE 8603582 A SE8603582 A SE 8603582A SE 8603582 A SE8603582 A SE 8603582A SE 460947 B SE460947 B SE 460947B
Authority
SE
Sweden
Prior art keywords
dopa
release
composition
hrs
granulate
Prior art date
Application number
SE8603582A
Other languages
English (en)
Swedish (sv)
Other versions
SE8603582L (sv
SE8603582D0 (sv
Inventor
C H Appelgren
E C Eskilsson
Original Assignee
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab
Priority to SE8603582A priority Critical patent/SE460947B/sv
Publication of SE8603582D0 publication Critical patent/SE8603582D0/xx
Priority to EP87850251A priority patent/EP0260236B1/fr
Priority to DE8787850251T priority patent/DE3766200D1/de
Priority to AT87850251T priority patent/ATE58292T1/de
Priority to ES198787850251T priority patent/ES2036221T3/es
Priority to HU873749A priority patent/HU197211B/hu
Priority to DK442287A priority patent/DK442287A/da
Priority to MX007910A priority patent/MX172918B/es
Priority to DD87306327A priority patent/DD286107A5/de
Priority to NO873589A priority patent/NO176549C/no
Priority to CA000545254A priority patent/CA1298198C/fr
Priority to FI873672A priority patent/FI86689C/fi
Priority to JP62210363A priority patent/JPH0662405B2/ja
Priority to PT85591A priority patent/PT85591B/pt
Publication of SE8603582L publication Critical patent/SE8603582L/xx
Priority to US07/378,423 priority patent/US4981695A/en
Publication of SE460947B publication Critical patent/SE460947B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
SE8603582A 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa SE460947B (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa
EP87850251A EP0260236B1 (fr) 1986-08-26 1987-08-21 Composition contenant de la L-dopa
DE8787850251T DE3766200D1 (de) 1986-08-26 1987-08-21 L-dopa enthaltendes arzneimittel.
AT87850251T ATE58292T1 (de) 1986-08-26 1987-08-21 L-dopa enthaltendes arzneimittel.
ES198787850251T ES2036221T3 (es) 1986-08-26 1987-08-21 Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.
FI873672A FI86689C (fi) 1986-08-26 1987-08-25 Foerfarande foer framstaellning av en multipel-unit-doskomposition, som innehaoller l-dopa som farmaceutiskt aktiv substans
DK442287A DK442287A (da) 1986-08-26 1987-08-25 Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
HU873749A HU197211B (en) 1986-08-26 1987-08-25 Process for producing pharmaceutical composition containing l-dopa as active component coated with coating for regulating release of the active components
MX007910A MX172918B (es) 1986-08-26 1987-08-25 Composicion a base de l-3,4-dihidroxifenilalanina
DD87306327A DD286107A5 (de) 1986-08-26 1987-08-25 Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt
NO873589A NO176549C (no) 1986-08-26 1987-08-25 Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk
CA000545254A CA1298198C (fr) 1986-08-26 1987-08-25 Composition comportant de la l-dopa
JP62210363A JPH0662405B2 (ja) 1986-08-26 1987-08-26 Ｌ―ドーパ含有組成物
PT85591A PT85591B (pt) 1986-08-26 1987-08-26 Processo para a preparacao de composicoes farmaceuticas sob a forma de dose unitaria-multipla contendo l-dopa
US07/378,423 US4981695A (en) 1986-08-26 1989-07-12 Composition comprising L-dopa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (3)

Publication Number Publication Date
SE8603582D0 SE8603582D0 (sv) 1986-08-26
SE8603582L SE8603582L (sv) 1988-02-27
SE460947B true SE460947B (sv) 1989-12-11

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Country Status (15)

Country Link
US (1) US4981695A (fr)
EP (1) EP0260236B1 (fr)
JP (1) JPH0662405B2 (fr)
AT (1) ATE58292T1 (fr)
CA (1) CA1298198C (fr)
DD (1) DD286107A5 (fr)
DE (1) DE3766200D1 (fr)
DK (1) DK442287A (fr)
ES (1) ES2036221T3 (fr)
FI (1) FI86689C (fr)
HU (1) HU197211B (fr)
MX (1) MX172918B (fr)
NO (1) NO176549C (fr)
PT (1) PT85591B (fr)
SE (1) SE460947B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
CA2007055A1 (fr) * 1989-01-06 1990-07-06 Garth Boehm Forme posologique de theophylline
CA2007181C (fr) * 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
US7872030B2 (en) * 2001-07-26 2011-01-18 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
MXPA04009123A (es) * 2002-03-21 2005-09-08 C Hinz Martin Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina.
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
JP2007509974A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ３−アミノプロピル−ｎ−ブチルホスフィン酸の増大した吸収のための組成物および薬用量形態
EP1697481A2 (fr) * 2003-12-09 2006-09-06 Spherics, Inc. Polymeres bioadhesifs a fonction catechol
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20090227673A1 (en) * 2006-01-13 2009-09-10 Bao Ting Zhu Method and Composition for the Treatment of Parkinson's Disease
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (fr) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
HUT44438A (en) 1988-03-28
JPS63139128A (ja) 1988-06-10
SE8603582L (sv) 1988-02-27
NO873589L (no) 1988-02-29
DE3766200D1 (de) 1990-12-20
CA1298198C (fr) 1992-03-31
NO873589D0 (no) 1987-08-25
MX172918B (es) 1994-01-21
NO176549B (no) 1995-01-16
EP0260236A1 (fr) 1988-03-16
US4981695A (en) 1991-01-01
SE8603582D0 (sv) 1986-08-26
FI86689C (fi) 1992-10-12
EP0260236B1 (fr) 1990-11-14
PT85591A (en) 1987-09-01
FI873672A0 (fi) 1987-08-25
FI86689B (fi) 1992-06-30
DK442287A (da) 1988-02-27
DK442287D0 (da) 1987-08-25
JPH0662405B2 (ja) 1994-08-17
DD286107A5 (de) 1991-01-17
NO176549C (no) 1995-04-26
ATE58292T1 (de) 1990-11-15
PT85591B (pt) 1990-05-31
FI873672A (fi) 1988-02-27
ES2036221T3 (es) 1993-05-16
HU197211B (en) 1989-03-28

Similar Documents

Publication Publication Date Title
SE460947B (sv) En multiple-unit-dos komposition av l-dopa
US8101209B2 (en) Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2518882B2 (ja) 被覆膜及びそれから調製された組成物
US4794001A (en) Formulations providing three distinct releases
ES2226886T3 (es) Forma de administracion de accion retardada que contiene sacarinato de tramadol.
FI84556B (fi) Foerfarande foer framstaellning av en formulation av kefaklor med laong verkan.
US4309404A (en) Sustained release pharmaceutical compositions
US6214385B1 (en) Controlled absorption diltiazem pharmaceutical formulation
EP0711152B1 (fr) Formes galeniques pour une administration orale, ayant une couche de poudre
US4462991A (en) Method of increasing oral absorption of polar bioactive agents
CA1323576C (fr) Preparation de diclofenac sodium, a action prolongee
IE59200B1 (en) Therapeutic compositions for oral administration
AU2007267159B2 (en) Lipoic acid pellets
US7611730B2 (en) Tramadol-based medicament
US20110189269A1 (en) Extended release composition containing tramadol
US20070098786A1 (en) Enteric valproic acid
EP0418597A2 (fr) Compositions pharmaceutiques à libération contrôlée contenant des inhibiteurs de l'anhydrase carbonique à partir de granules sphériques sous forme d'une dose unitaire orale en capsule
KR20190080875A (ko) 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트
US20030215506A1 (en) Methods and compositions for enhancement of creatine transport
US6994873B2 (en) Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
SE462779B (sv) Farmaceutisk komposition innehaallande n-acetylcystein i en kaerna belagd med hydroxipropylmetylcellulosaftalat
EP1539113A2 (fr) Composition pharmaceutique a liberation modifiee
EP0287536A1 (fr) Composition pharmaceutique de quinidine
JP2009514784A (ja) 経口リバビリン医薬組成物
IE62643B1 (en) Synergistic combination of decarboxylase inhibitors and L-dopa pellets

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8603582-1

Effective date: 19920306

Format of ref document f/p: F